Odyssey Therapeutics, founded in 2021, is a biotechnology startup focused on developing next-generation precision medicines for cancer and inflammatory diseases. The company emphasizes its class-leading speed, efficiency, and rigor through a highly integrated drug hunting engine.
The startup recently secured a significant $101.00M Series C investment on 05 December 2023. The round was backed by a notable group of investors including HBM Healthcare Investments, General Catalyst, T. Rowe Price, Fidelity, Foresite Capital, Woodline Partners, Ascenta Capital, Global BioAccess Fund, The Healthcare Innovation Investment, and BlackMars Capital.
Odyssey Therapeutics operates in the biotechnology, healthcare, and health and wellness industries, leveraging its specialized focus on precision medicines to address critical medical needs. However, the company has recently faced challenges related to recruitment fraud, prompting a cautionary message on its Careers page.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $101.00M | 10 |
|
05 Dec 2023 |
| Series B | $168.00M | - | 13 Oct 2022 | |
| Series A | $218.00M | - | 07 Dec 2021 |
No recent news or press coverage available for Odyssey Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
